Clinical Oncology: Case Reports

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Nikolas von Bubnoff Author

Bubnoff896@hotmail.com

Subjects of specialization
Kinase Oncology Hematology Cancer Biology Cancer Therapy Receptor Cells Phosphorylation Cell Death Apoptosis

Affiliation
Department of Hematology and Oncology, Medical Center, University of Schleswig- Holstein, L

Biography

Dr. Nikolas von Bubnoff is working as scientist and professor at Department of Hematology and Oncology, Medical Center, University of Schleswig- Holstein, Lübeck, Germany. The author has specalization in cancer, cancer oncology, chemotherapy, Carcinogenesis, Chemotherapy

Publications

Case Report Subscription

Autoimmune Toxicity Following Nivolumab and Ipilimumab Therapy For Hepatocellular Carcinoma-An Interdisciplinary Challenge

Author(s):

Matthias Mezger, Cara Harms, Karolin Schmoll, Aneke Gansewig, Ingo Eitel, Nikolas von Bubnoff and Tobias Graf

Abstract

Over the last years, several new drugs have been launched for the treatment of cancer. Immune checkpoint blockade suppresses intrinsic down-regulators of immunity, such as cytotoxic T-lymphocyte Antigen 4 (CTLA-4) and Programmed Cell Death 1 (PD-1) or its ligand, Programmed Cell Death Ligand 1 (PD-L1). Immune checkpoint blockade enhances patient´s immune system and increased survival rates for different cancer subtypes. However, immune checkpoint blockade can lead to autoimmunity with a multitude of side effects that involve the heart, gastrointestinal tract, endocrine glands, skin, CNS and liver. We here present the case of a patient who was admitted to the emergency department with stroke- like symptoms. Whilst monitoring on stroke- unit was o... view more»

Abstract HTML PDF

Social Media

Google Scholars / Researchers Sites

Explore SciTechnol

GET THE APP